CRISPR Therapeutics AG (CRSP)
55.61
-0.80
(-1.42%)
USD |
NASDAQ |
Apr 24, 16:00
55.93
+0.32
(+0.58%)
After-Hours: 20:00
CRISPR Therapeutics Cash from Investing (TTM): 374.65M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 374.65M |
| September 30, 2023 | 280.57M |
| June 30, 2023 | 246.68M |
| March 31, 2023 | -26.31M |
| December 31, 2022 | -258.66M |
| September 30, 2022 | -91.84M |
| June 30, 2022 | -744.48M |
| March 31, 2022 | -982.05M |
| December 31, 2021 | -1.035B |
| September 30, 2021 | -1.231B |
| June 30, 2021 | -996.11M |
| March 31, 2021 | -706.08M |
| December 31, 2020 | -541.17M |
| September 30, 2020 | -329.87M |
| June 30, 2020 | -2.00M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.569M |
| December 31, 2019 | 1.325M |
| September 30, 2019 | -6.732M |
| June 30, 2019 | -4.966M |
| March 31, 2019 | -3.315M |
| December 31, 2018 | -2.773M |
| September 30, 2018 | -1.978M |
| June 30, 2018 | -4.777M |
| March 31, 2018 | -5.584M |
| December 31, 2017 | -8.314M |
| September 30, 2017 | 6.663M |
| June 30, 2017 | 8.648M |
| March 31, 2017 | 8.931M |
| December 31, 2016 | 31.88M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.231B
Minimum
Sep 2021
374.65M
Maximum
Dec 2023
-318.63M
Average
-91.84M
Median
Sep 2022
Cash from Investing (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | -3.142B |
| Intellia Therapeutics Inc | -31.35M |
| Novartis AG | 5.596B |
| Verve Therapeutics Inc | 27.69M |
| AC Immune SA | 73.11M |